Literature DB >> 986585

Guanidine and germine in Eaton-Lambert syndrome.

M Cherington.   

Abstract

A 43-year-old man with Eaton-Lambert syndrome developed chronic interstitial nephritis after 4 years of guanidine hydrochloride therapy. The diagnosis of Eaton-Lambert syndrome was confirmed by clinical neurophysiologic studies and by intracellular electrode studies of end-plate potentials from an intercostal muscle biopsy. Because guanidine had toxic effects in this patient, an alternative form of therapy was tried. Germine-3-acetate (500 mg per day orally) resulted in clinical and electric improvement of the myasthenic syndrome. However, the sensory side effects of numbness of the limbs and unpleasant taste were sufficiently annoying that germine was discontinued.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 986585     DOI: 10.1212/wnl.26.10.944

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  4-aminopyridine--a new drug tested in the treatment of Eaton-Lambert syndrome.

Authors:  H Lundh; O Nilsson; I Rosén
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-11       Impact factor: 10.154

Review 2.  Lambert-Eaton myasthenic syndrome.

Authors:  U Seneviratne; R de Silva
Journal:  Postgrad Med J       Date:  1999-09       Impact factor: 2.401

3.  Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine.

Authors:  D B Sanders; Y I Kim; J F Howard; C A Goetsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-11       Impact factor: 10.154

4.  A neuromuscular transmission disorder: combined myasthenia gravis and Lambert Eaton syndrome in one patient.

Authors:  M J Taphoorn; H Van Duijn; E C Wolters
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

Review 5.  3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.

Authors:  J Molgó; J M Guglielmi
Journal:  Pflugers Arch       Date:  1996       Impact factor: 3.657

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.